Evaluation of Risk of hEpatocellular Carcinoma

Who May Qualify: - Diagnosis of NAFLD or cryptogenic liver disease, allowing a more liberal alcohol intake limit (\<60/40 g/day in M/F), so as to also include subjects with a moderate alcoholic component of liver disease, an important factor given the high epidemiological burden of this group - Age between 45 and 75 years - Any of the following criteria: - F3-F4 fibrosis, determined histologically, or by non-invasive techniques (stiffness \> 7.9 kPa at Fibroscan and positivity at the NAFLD fibrosis score or at APRI or at FIB4), or evidence of cirrhosis deriving from biochemical tests or imaging methods; - Family history of primary liver cancer in first degree parentage, or carrier status of rare mutations associated with the development of HCC (such as mutations in APOB and TERT) - Male patient with type 2 diabetes or obesity carrying at least three genetic variants in PNPLA3, TM6SF2, MBOAT7. - Willingness to sign the willing to sign a consent form. Who Should NOT Join This Trial: - Alcohol intake \>60/40 g/day in M/F - Chronic viral or autoimmune hepatitis - Any previously diagnosed genetic liver disease associated with increased risk of HCC (such as hereditary hemochromatosis, Wilson's disease, Alpha-1 Antitrypsin deficiency) - Use of drugs known to induce steatosis and liver disease - HCC diagnosed before the study start date. - Other pathological conditions with a prognosis of less than two years. Always talk to your doctor about whether this trial is right for you.